©The Author(s) 2016.
World J Stem Cells. Jul 26, 2016; 8(7): 223-230
Published online Jul 26, 2016. doi: 10.4252/wjsc.v8.i7.223
Published online Jul 26, 2016. doi: 10.4252/wjsc.v8.i7.223
Table 2 Number and percentage of patients who showed improvement by at least one grade of Nutech functional score at baseline to the end of T1 (n = 95)
| Parameter | Patients (n) affected at baseline | Improved n (%) |
| FBS | 95 | 93 (97.9) |
| HbA1c | 93 | 90 (96.8) |
| Insulin level | 91 | 88 (96.7) |
| Insulin with medication | 92 | 88 (95.7) |
| Medication level | 93 | 82 (88.2) |
| Post-prandial blood insulin 60 min | 95 | 92 (96.8) |
| Post-prandial blood sugar | 95 | 92 (96.8) |
| Pre-dinner | 95 | 93 (97.9) |
| Secondary complication | 84 | 79 (94.0) |
| Serum insulin | 94 | 80 (85.1) |
| Serum peptide | 90 | 87 (96.7) |
- Citation: Shroff G. Therapeutic potential of human embryonic stem cells in type 2 diabetes mellitus. World J Stem Cells 2016; 8(7): 223-230
- URL: https://www.wjgnet.com/1948-0210/full/v8/i7/223.htm
- DOI: https://dx.doi.org/10.4252/wjsc.v8.i7.223